RBC Capital reiterates Acadia Pharmaceuticals stock rating on patent developments
RBC Capital maintained its Outperform rating on Acadia Pharmaceuticals (NASDAQ:ACAD) with a $37.00 price target, citing attractive valuation and reduced risk around Nuplazid revenue. The stock trades at $20.08 with a P/E ratio of 9.09 and PEG ratio of 0.14. Analysts revised earnings upwards, but recent Phase 2 trial results missed primary endpoint, leading to adjusted price targets.
How this was made
The 30-second read
Why it matters
The trial miss and subsequent analyst target reductions suggest short‑term downside, but the reaffirmed Outperform rating may cushion the move.
Market read
The news provides fresh clinical data and analyst reactions that could influence ACAD's price in the near term.
What to watch
Potential upside from Acadia's other pipeline assets and existing Nuplazid revenue.
Background
Acadia Pharmaceuticals (NASDAQ:ACAD) focuses on CNS disorders. Recent analyst coverage highlighted a Phase 2 trial miss for remlifanserin and reaffirmed a bullish rating despite the setback.
Ticker impact
RBC Capital reiterated its Outperform rating on Acadia Pharmaceuticals and noted a Phase 2 trial miss for remlifanserin, prompting analyst target cuts.
likely downward pressure as the market prices in the missed primary endpoint.
The trial result is a fresh clinical data point; analysts have already lowered price targets, indicating a bearish outlook.
Market effects
Biotech sector may see heightened scrutiny of CNS‑focused trials.
U.S. biotech stocks could face modest pullback.
Limited to investors tracking clinical outcomes in neuro‑psychiatric drugs.
Counterpoint
Some investors may view the reaffirmed Outperform rating as a buying opportunity if the trial miss is deemed non‑material.
Key entities
- AnalystRBC Capital
Maintained Outperform rating and $37 price target.
- AnalystGoldman Sachs
Reiterated Sell rating with $17 price target after trial miss.
